Form 4: Director Liam Ratcliffe Receives OnKure Stock Options

Director Liam Ratcliffe was granted 1,275 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Summary

• Director Liam Ratcliffe acquired 1,275 stock options in OnKure Therapeutics, Inc. (OKUR).
• The options have an exercise price of $4.30 per share.
• The grant date for the transaction was June 4, 2026.
• The options are scheduled to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon potential future exercise of options.

Risks

• The value of the options is dependent on the future market performance of OKUR common stock.

Future Outlook

The options vest 100% on the earlier of June 4, 2027, or the day prior to the issuer's next annual meeting of stockholders, contingent upon continued service.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align governance with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for small-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders due to the small volume of options granted.

Next Steps

• Vesting of options on June 4, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Trading, Stock Options, Director Compensation